Skip to main content

Advertisement

Table 5 Multivariate Cox proportional hazards regression for progression free (PFS) and overall survival (OS) in a model including post-treatment laboratory analyses after one cycle of docetaxel (q1) with either continuous or categorical CTC-counts

From: Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients

  PFS OS
CTC-assessment Values in model Hazard ratio 95 % CI p= Hazard ratio 95 % CI p=
Continuous CTC-values CTC-value Continuous 1.02 0.99-1.05 0.14 1.02 1.01-1.04 0.04
PSA-value ≥30 % decline 1.8 0.6-5.6 0.3 2.6 0.9-7.78 0.09
Lactate dehydrogenase ≤ ULN vs. >ULN 1.2 0.2-10.2 0.8 0.7 0.1-3.4 0.65
Alkaline phosphatase ≤ ULN vs. >ULN 3.2 0.95-10.99 0.06 3.4 1.1-10.3 0.03
Hemoglobin < LLN vs. ≥LLN 2.7 0.3-28.4 0.4 1.7 0.2-17.0 0.63
Categorical CTC-counts CTC-count <5 CTCs vs. ≥5 CTCs 3.9 1.1-13.8 0.04 4.9 1.6-15.7 0.007
PSA-value ≥30 % decline 1.8 0.6-5.3 0.3 3.0 1.03-8.8 0.04
Lactate ehydrogenase ≤ ULN vs. >ULN 1.5 0.2-11.8 0.7 0.8 0.2-3.9 0.84
Alkaline phosphatase ≤ ULN vs. >ULN 1.9 0.5-7.4 0.4 2.0 0.6-6.5 0.27
Hemoglobin < LLN vs. ≥LLN 3.3 0.3-34.3 0.3 2.2 0.2-21.0 0.5